No Data
HK stocks abnormal movement | Simcere Pharma (02096) surged over 12% with high volume, turnover exceeded 0.2 billion Hong Kong dollars, the company is expected to welcome multiple catalysts.
Simcere pharma (02096) surged over 12%, currently up 12.38%, reported at 6.99 HKD, with a trading volume of 0.233 billion HKD.
The new policy of prepayment of medical insurance fund has been released, and the pharmaceutical sector has ushered in a sharp rise. Experts believe it may be a way for medical institutions to release funding pressure.
On the 11th, the "Notice on Prepayment of Medical Insurance Fund" was issued, requiring the unified and improved basic medical insurance fund prepayment system at the national level. Experts believe that the prepayment system can effectively alleviate the problem of pharmaceutical industry debt, accelerate the turnover of funds for pharmaceutical companies. The medical sector showed a significant upward trend today, with listed companies attributing the rise to investor sentiment.
Medical stocks collectively surged! Bullish news has arrived, the medical sector welcomes a catalyst.
The medical sector with lagging growth finally sees a catalyst! Analysis believes that for medical institutions, prepayment of medical insurance funds helps optimize and improve the daily operation cash flow and financial pressure of medical institutions, reducing the potential receivables and bad debt risks caused by unpaid medical insurance expenses. For medical insurance, it enhances the settlement efficiency and encourages the active diagnosis and treatment enthusiasm of medical institutions.
Multiple bullish factors boost pharmaceutical stocks listed in Hong Kong, institutions say they still face this risk in the short term.
①What are the policy measures to support the field of innovative drugs? ②What unfavorable effects on domestic pharmaceutical stocks might Trump's election bring about?
Lu Chongmao: The "1+" mechanism has approved a total of 5 new drug applications, with the cost of 2 drugs decreasing by nearly 30%.
Dr. Constance Chan, Director of Health, stated at the Legislative Council meeting today (8th) that since the new drug approval mechanism ("1+1" mechanism) took effect, the Department of Health has received inquiries from more than 80 pharmaceutical companies, totaling over 260, and has approved a total of 5 new drug applications. These include 2 treatments for metastatic colorectal cancer, 1 treatment for paroxysmal nocturnal hemoglobinuria, 2 treatments for patients with parathyroid cancer and a certain type of hypercalcemia in patients with primary hyperparathyroidism. Dr. Constance Chan revealed that two of the new drugs for the treatment of metastatic colorectal cancer have been included in the public hospital authority's list of specialty drugs. The public hospital authority has also successfully completed procurement discussions.
Hong Kong stocks have seen unusual movements, with CRO concept stocks generally under pressure. The emotions are influenced by the results of the USA election. Institutions point out that the probability of the Biosecurity Law being an independent law may
CRO concept stocks are generally under pressure. As of the time of publication, GenScript Biotech (01548) fell by 6.68% to HKD 10.9; Viva Biotech (01873) fell by 3.16% to HKD 0.92; Pharmaron (03759) fell by 2.64% to HKD 16.22.
No Data
No Data